1 Study protocol

## 2 The CRCbiome study: a large prospective cohort study examining the role of

# 3 lifestyle and the gut microbiome in colorectal cancer screening participants

- 4
- 5 Ane Sørlie Kværner<sup>a</sup>, Einar Birkeland<sup>b</sup>, Cecilie Bucher-Johannessen<sup>b,c</sup>, Elina Vinberg<sup>b</sup>, Jan
- 6 Inge Nordby<sup>d</sup>, Harri Kangas<sup>e</sup>, Vahid Bemanian<sup>f</sup>, Pekka Ellonen<sup>e</sup>, Edoardo Botteri<sup>a,b</sup>, Erik
- 7 Natvig<sup>a</sup>, Torbjørn Rognes<sup>g,h</sup>, Eivind Hovig<sup>c,g</sup>, Robert Lyle<sup>i,j</sup>, Ole Herman Ambur<sup>k,l</sup>, Willem M.
- 8 de Vos<sup>m,n</sup>, Scott Bultman<sup>o</sup>, Anette Hjartåker<sup>p</sup>, Rikard Landberg<sup>q</sup>, Mingyang Song<sup>r,s,t</sup>, Giske
- 9 Ursin<sup>u</sup>, Kristin Ranheim Randel<sup>a</sup>, Thomas de Lange<sup>v,w,x</sup>, Geir Hoff<sup>a,y</sup>, Øyvind Holme<sup>a,z,æ</sup>,
- 10 Paula Berstad<sup>a</sup><sup>#</sup>, Trine B. Rounge<sup>b,g</sup><sup>#</sup>
- 11 <sup>#</sup>equal contribution
- 12

# 13 Author affiliations

- <sup>14</sup> <sup>a</sup>Section for Colorectal Cancer Screening, Cancer Registry of Norway, Oslo, Norway
- <sup>15</sup> <sup>b</sup>Department of Research, Cancer Registry of Norway, Oslo, Norway
- <sup>16</sup> <sup>c</sup>Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium
- 17 Hospital, Oslo University Hospital, Oslo, Norway
- <sup>18</sup> <sup>d</sup>Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway
- <sup>e</sup>Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Helsinki, Finland
- <sup>20</sup> <sup>f</sup>Department of Multidisciplinary Laboratory Science and Medical Biochemistry, Genetic
- 21 Unit, Akershus University Hospital, Lørenskog, Norway.
- 22 <sup>g</sup>Centre for Bioinformatics, Department of Informatics, University of Oslo, Oslo, Norway
- <sup>23</sup> <sup>h</sup>Department of Microbiology, Oslo University Hospital, Oslo, Norway
- <sup>1</sup>Department of Medical Genetics, Oslo University Hospital and University of Oslo, Oslo,
   Norway
- <sup>26</sup> <sup>J</sup>Centre for Fertility and Health, Norwegian Institute of Public Health, Oslo, Norway.
- <sup>27</sup> <sup>k</sup>Department of Microbiology and Infection Control, Akershus University Hospital,
- 28 Lørenskog, Norway
- <sup>29</sup> <sup>1</sup>Department of Natural Sciences and Health, Oslo Metropolitan University, Oslo, Norway
- <sup>30</sup> <sup>m</sup>Laboratory of Microbiology, Wageningen University, Wageningen, the Netherlands
- <sup>n</sup>Human Microbiome Research Program, Faculty of Medicine, University of Helsinki,
- 32 Helsinki, Finland

It is made available under a CC-BY-NC 4.0 International license .

- <sup>33</sup> <sup>o</sup>Department of Genetics and Lineberger Comprehensive Cancer Center, University of North
- 34 Carolina, Chapel Hill, NC, USA
- 35 <sup>p</sup>Department of Nutrition, University of Oslo, Oslo, Norway
- <sup>4</sup>Department of Biology and Biological Engineering, Division of Food and Nutrition Science,
- 37 Chalmers University of Technology, Gothenburg, Sweden.
- <sup>38</sup> <sup>r</sup>Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA,
- 39 USA.
- 40 <sup>s</sup>Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
- 41 <sup>t</sup>Clinical and Translational Epidemiology Unit and Division of Gastroenterology,
- 42 Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
- 43 <sup>u</sup>Cancer Registry of Norway, Oslo, Norway
- 44 <sup>v</sup>Medical Department, Sahlgrenska University Hospital-Mölndal, Mölndal, Sweden
- 45 <sup>w</sup>Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of
- 46 Gothenburg. Gothenburg, Sweden
- 47 <sup>x</sup>Department of Medical Research, Bærum Hospital, Bærum, Norway
- 48 <sup>y</sup>Department of Research, Telemark Hospital, Skien, Norway
- 49 <sup>z</sup>Department of Medicine, Sorlandet Hospital Kristiansand, Kristiansand, Norway
- <sup>x</sup>Institute for Health and Society, University of Oslo, Oslo, Norway
- 51

## 52 **Corresponding authors**

- 53 Paula Berstad, Section for Colorectal Cancer Screening, Cancer Registry of Norway, Oslo,
- 54 Norway
- 55 Tel: +47 93293235
- 56 E-mail: paula.berstad@kreftregisteret.no
- 57 &
- 58 Trine B. Rounge, Department of Research, Cancer Registry of Norway, Oslo, Norway
- 59 Tel: +47 99604304
- 60 E-mail: trine.rounge@kreftregisteret.no

It is made available under a CC-BY-NC 4.0 International license .

#### 61 Abstract

62 **Background**: Colorectal cancer (CRC) screening reduces CRC incidence and mortality. 63 However, current screening methods are either hampered by invasiveness or suboptimal 64 performance, limiting their effectiveness as primary screening methods. To aid in the 65 development of a non-invasive screening test with improved sensitivity and specificity, we 66 have initiated a prospective biomarker study (CRCbiome), nested within a large randomized 67 CRC screening trial in Norway. We aim to develop a microbiome-based classification 68 algorithm to identify advanced colorectal lesions in screening participants testing positive for 69 an immunochemical fecal occult blood test (FIT). We will also examine interactions with host 70 factors, diet, lifestyle and prescription drugs. The prospective nature of the study also enables 71 the analysis of changes in the gut microbiome following the removal of precancerous lesions. 72 **Methods**: The CRCbiome study recruits participants enrolled in the Bowel Cancer Screening 73 in Norway (BCSN) study, a randomized trial initiated in 2012 comparing once-only 74 sigmoidoscopy to repeated biennial FIT, where women and men aged 50-74 years at study 75 entry are invited to participate. Since 2017, participants randomized to FIT screening with a 76 positive test result have been invited to join the CRCbiome study. Self-reported diet, lifestyle 77 and demographic data are collected prior to colonoscopy after the positive FIT-test (baseline). 78 Screening data, including colonoscopy findings are obtained from the BCSN database. Fecal 79 samples for gut microbiome analyses are collected both before and 2 and 12 months after 80 colonoscopy. Samples are analyzed using metagenome sequencing, with taxonomy profiles, 81 and gene and pathway content as primary measures. CRCbiome data will also be linked to 82 national registries to obtain information on prescription histories and cancer relevant 83 outcomes occurring during the 10 year follow-up period. 84 Discussion: The CRCbiome study will increase our understanding of how the gut

biscussion. The exceptione study with increase our understanding of now the gut
microbiome, in combination with lifestyle and environmental factors, influences the early
stages of colorectal carcinogenesis. This knowledge will be crucial to develop microbiomebased screening tools for CRC. By evaluating biomarker performance in a screening setting,
using samples from the target population, the generalizability of the findings to future
screening cohorts is likely to be high.

90 Trial Registration: ClinicalTrials.gov Identifier: NCT01538550

- 91 Keywords: Diet, lifestyle, prescription drugs, gut microbiome, metagenomics sequencing,
- 92 biomarkers, screening, FIT, iFOBT, colonoscopy, adenoma, colorectal cancer, advanced
- 93 neoplasia

It is made available under a CC-BY-NC 4.0 International license .

### 94 Background

95 Colorectal cancer (CRC) is a major global health burden, accounting for nearly 10% of all 96 cancers diagnosed and cancer-related deaths each year (1). Although a decline in the age-97 standardized mortality rate has been observed over the past two to three decades in many 98 countries (2–4), death rates remain high, particularly when diagnosed at later stages (5-year 99 survival rate of 13% for metastatic disease compared to 90% when diagnosed at a localized 100 stage) (1,5). The significant contribution to global cancer deaths, together with the worrying 101 rise in incidence rates seen globally (3), especially the recent increase among younger age 102 groups (6,7), highlights the need for widespread prevention strategies that are both effective 103 and feasible on a large-scale basis.

104 There are two major precursor lesions of CRC: adenomatous polyps, accounting for the

105 majority of cases, and serrated lesions, estimated to underlie up to 30% of CRC (8). The

106 progression of precursor lesions to CRC is a long-term process, spanning a period of 10-15

107 years for most lesions (9). During this long latency period, most cancers develop

108 asymptomatically, making them difficult to detect at a preclinical stage. Therefore,

109 international guidelines recommend screening, with the aim of detection and removal of

110 precancerous lesions to prevent cancer from occurring, or to detect cancer at the earliest stage

111 possible (10–13).

112 Screening has been shown to reduce both CRC incidence (14–17) and mortality (14–21) in

113 randomized controlled trials, even though current screening methods have known limitations

114 (22). At present, the most commonly used screening method is the fecal immunochemical test

115 (FIT) for occult blood, having mostly replaced the less sensitive guaiac-based fecal occult

116 blood test (gFOBT) (23). Despite being more sensitive, performance characteristics are still

suboptimal with regards to sensitivity and specificity, resulting in both missed neoplasms and

118 unnecessary colonoscopy referrals (22). Of particular concern has been the limited

119 performance in detecting precancerous lesions, representing a missed opportunity given the

120 great potential for cancer prevention following removal of these lesions. There is also

121 evidence that current screening methods perform worse for right-sided tumors, compared to

122 left-sided ones (24), as well as in women compared to men (25,26). Thus, there is a

123 requirement for screening methods and tools with improved performance for the entire

124 screening population.

It is made available under a CC-BY-NC 4.0 International license .

125 Both observational and experimental evidence point to an important role of the gut 126 microbiome in development and progression of CRC (27). Numerous studies have 127 demonstrated differences in the gut microbiome of tumor and adjacent non-tumor tissue 128 (28,29), as well as in stool samples from CRC patients and healthy controls (30-38). 129 Typically, the presence of a colorectal tumor has been associated with enrichment of 130 pathogenic bacterial species, such as Fusobacterium nucleatum, Escherichia coli and 131 *Bacteroides fragilis*, and depletion of potentially protective bacteria (e.g. producers of short 132 chain fatty acid (SCFAs)) (27). Although less studied, there are reports indicating that 133 subjects with precancerous lesions display shifts in their microbial profiles (30,33,39), 134 suggesting the presence of microbial changes at early stages of colorectal carcinogenesis. 135 The gut microbiome is heavily influenced by the environment (40). Established risk factors 136 for CRC, such as excess body weight, physical inactivity and a Western dietary pattern 137 (typically high in red and processed meat and low in whole grains and dietary fiber) and 138 protective factors, such as dairy products and use of certain medications (e.g. aspirin/NSAIDs 139 and metformin) are suggested to modify the gut microbiome (41). At the same time, 140 accumulating evidence indicates that modifications of the gut microbiome may allow 141 environmental risk factors to induce malignant transformation (42,43). This highlights the 142 complex relationship between the environment and the microbiome in the etiology of CRC. 143 The connection between a potentially pathogenic gut microbiome and CRC has resulted in a 144 growing interest in the use of gut microbial biomarkers as screening tests for early detection 145 of precancerous and cancerous lesions. Several studies have shown that combining 146 microbiome data with the results of established screening methods, such as gFOBT or FIT, 147 substantially increase the ability to classify groups of individuals with healthy colons, 148 adenoma and CRC (30,33,34). Two recent meta-analyses of metagenome data showed that 149 both taxonomic and functional gut microbial profiles predicted CRC at time of diagnosis with 150 high accuracy (44, 45). 151 Although results from previous biomarker studies are promising, no microbial biomarkers are

152 currently used in national screening programs. In order to advance the utility of the gut

153 microbiome in screening, additional data from prospective studies are needed.

It is made available under a CC-BY-NC 4.0 International license .

### 154 **Objectives**

- 155 The primary aim of the CRCbiome study is to develop a classification algorithm for
- 156 identification of advanced colorectal lesions based on the screened individuals' gut
- 157 metagenome, demographics and lifestyle. Secondary aims are to provide a deeper
- understanding of how the gut microbiome evolves prior to a cancer diagnosis, as well as its
- 159 interactions with host, lifestyle and environmental factors:
- 160 I. Identification of associations of the gut microbiome with advanced colorectal
  161 lesions, defined as presence of advanced adenomas, advanced serrated lesions or
  162 CRC, at baseline
- 163 II. Examination of interactions of the gut microbiome with host factors, diet, lifestyle
  164 and medication use on risk of advanced colorectal lesions at baseline
- 165 III. Description of changes in the gut microbiome following removal of precursor166 lesions of CRC
- 167 Long-term outcomes (i.e. incidence and mortality of advanced colorectal lesions) will be
- 168 examined by means of passive follow-up using data from the national registries. The outcome
- assessment will be aligned with the 10 year follow-up of the Bowel Cancer Screening in
- 170 Norway (BCSN) trial (46), from which the CRCbiome study recruits participants.

It is made available under a CC-BY-NC 4.0 International license .

#### 171 Methods

## 172 Study design

173 The CRCbiome study is a prospective cohort study nested within the BCSN trial, which is a 174 pilot for a national screening program, organized by the Cancer Registry of Norway . The 175 BCSN study is designed as a randomized trial comparing once-only sigmoidoscopy with FIT 176 tests every two years for a maximum of four rounds (46). The trial was started in 2012, with 177 follow-up FIT rounds scheduled to be completed in 2024. Participants randomized to the FIT 178 group who test positive (i.e. hemoglobin >15 mcg/g feces), are referred for follow-up 179 colonoscopy at their local screening center. Neoplastic lesions detected as part of the 180 screening examination are removed during colonoscopy or elective surgery, if necessary.

181 Biennial FIT testing is discontinued for those having undergone colonoscopy following a

182 positive FIT test.

183 The CRCbiome study recruits participants from the BCSN trial who receive a positive FIT

184 test. FIT positive participants are selected since they are referred to follow-up colonoscopies

in line with the BCSN study protocol and will have detailed clinicopathological information.

186 Conversely, as no diagnostic information is available for those with a negative FIT test, these

are not included in the CRCbiome study. Of note, as recruitment for the CRCbiome study

188 started five years after commencement of the BCSN trial, those with positive FIT findings in

the first and initial part of the second round of screening in the BCSN were not invited. Even

so, due to incomplete participation in the first round of FIT testing, 10% of the CRCbiome

191 participants had their inclusion sample as their first screening test.

192 Participants are invited to the CRCbiome study prior to their colonoscopy examination. The

193 invitation includes an information letter and two questionnaires (further details given below).

194 FIT-positive fecal samples from the BCSN are retrieved following enrolment and represent

the baseline sample of the CRCbiome study. Participants are thereafter contacted 2 and 12

196 months after colonoscopy for collection of follow-up fecal samples using the same sampling

method. Fecal samples are processed for microbiome analysis as they become available to theproject.

199 Based on the colonoscopy examination, participants are categorized into diagnostic groups

200 ranging from no pathological findings to presence of advanced lesions and CRC. The groups

selected for analyses will vary depending on aim (see <u>Outcome variables</u> for a complete

202 description of outcomes).

It is made available under a CC-BY-NC 4.0 International license .

- 203 Data collected in the CRCbiome study will be linked to national registries, including the
- 204 Norwegian Prescription Database (47) and the Cancer Registry of Norway (48). An overview
- 205 of the study design is shown in Figure 1. The design and handling of data in the CRCbiome
- study is in accordance with the STROBE guidelines for observational and metagenomics
- 207 studies (49–51).

### 208 Participants and eligibility

- 209 The BCSN trial includes 139,291 women and men aged 50-74 years in 2012, living in South-
- 210 East Norway. Of these, 70,096 have been randomized to FIT screening. So far, the cumulative
- 211 participation rate for the first three FIT rounds has been 68% (46). All screening participants
- 212 with a positive FIT test are eligible for the CRCbiome study. Recruitment for the CRCbiome
- study started in 2017, and will continue until a minimum of 2,700 participants have been
- invited. So far, 2,426 have been invited and 1,413 (58%) have agreed to participate. With the
- 215 current participation rate, we expect recruitment to be completed by March 2021 with a final
- 216 number of participants of about 1,600 (see below for the sample size considerations).
- 217 The main inclusion and exclusion criteria for the BCSN trial and the CRCbiome study are
- 218 listed in **Table 1**.

## 219 **Recruitment of participants**

- 220 Eligible subjects are invited after being informed about their positive FIT test and a
- 221 colonoscopy appointment has been scheduled. Invitations to the CRCbiome study, including
- the two questionnaires, are sent out by mail a minimum of four days prior to the colonoscopy.
- 223 Returning at least one of the two questionnaires is regarded as a consent to the study, and
- includes permission to collect, analyze and store fecal samples, and to retrieve information
- from questionnaires and health registries.
- Both the BCSN trial and the CRCbiome study have been approved by the Regional
- 227 Committee for Medical Research Ethics in South East Norway (Approval no.: 2011/1272 and
- 228 63148, respectively). The BCSN is also registered at clinicaltrials.gov (Clinical Trial (NCT)
- 229 no.: 01538550).

### 230 Outcome variables

- 231 For the first two aims, the outcome variable will be defined based on the colonoscopy result.
- 232 Participants will be grouped into four main categories: no confirmed neoplastic findings
- 233 (Group 1); non-advanced lesions (Group 2); advanced lesions (Group 3); and CRC (Group 4)
- 234 (Table 2). We may further subdivide lesions by clinicopathological features, including

It is made available under a CC-BY-NC 4.0 International license .

- histopathological subtype (e.g. adenomas versus serrated lesions) and site of occurrence
- 236 (proximal versus distal colon). Also of interest is the potential for distinct roles of
- 237 environmental factors and the gut microbiome in the two main pathways of colorectal
- 238 carcinogenesis: the adenoma-carcinoma pathway, and the serrated carcinoma pathway.
- 239 For the third aim, the outcome variable will be defined based on the metagenome data. We
- 240 will monitor several aspects of the gut microbiome, leveraging information derived from
- 241 metagenomic sequencing to describe the presence of bacterial strains and the functional
- 242 potential in paired samples during re-establishment of the gut microbiome following bowel
- cleansing and colonoscopy.
- Long-term effects in the study will be assessed 10 years after recruitment is completed. This
- will include an investigation of incidence and mortality of advanced colorectal lesions.

## 246 Clinical data, biological sampling and questionnaires

# 247 Assessment of clinical data

- As part of the BCSN (46), participants are contacted by a study nurse prior to follow-up
- 249 colonoscopy, to obtain information on medical history. This includes prior colonoscopies and
- 250 CT colonographies, comorbidities, drug use, gastrointestinal symptoms, smoking habits, and
- body weight and height (**Table 3**). A variety of data are collected in relation to the follow-up
- colonoscopy, including screening outcomes (i.e. presence and clinicopathological
- characterization of detected lesions) and cgaracteristics relevant to the endoscopic procedure
- 254 (Table 3). For all lesions detected, size, location, appearance, technique used for removal and
- tissue sampling, and completeness of removal are recorded. Both the medical history data and
- data collected as part of the follow-up colonoscopy are entered into a dedicated database by
- the responsible health care provider. A complete overview of the data collected in the BCSN
- trial can be found elsewhere (46).

## 259 Biological sampling and gut microbiome analysis

- 260 FIT sampling and storage
- 261 Sampling kits for stool sample collection are mailed to the participants three times during the
- study period. No restrictions on diet or medication use are required prior to sampling. Stool is
- collected using plastic sticks, which collect about 10 mg stool. The stool is then stored in 2 ml
- 264 of buffer containing HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), BSA
- 265 (Bovine serum albumin) and sodium azide. Samples are then packed in padded envelopes and
- 266 returned by mail to a laboratory at Oslo University Hospital for analysis and further storage at

- -80 °C. Shipping time is estimated to 3–10 days. Immunochemical testing for blood in feces is
- 268 performed continuously using the OC-Sensor Diana (Eiken Chemical, Tokyo, Japan) as
- samples are received at the laboratory.
- 270 DNA extraction
- 271 Thawed samples are transferred to three 500 ml aliquots from the sampling bottle using a
- 272 blood sampling needle (Vacuette) perforating the plastic lid. Samples are stored at -80 °C
- 273 until further processing.
- 274 Extraction of DNA is carried out using the QIAsymphony automated extraction system, using
- the QIAsymphony DSP Virus/Pathogen Midikit (Qiagen), after an off-board lysis protocol
- with some modifications. Each sample is lysed with bead-beating: a 500 µl sample aliquot is
- transferred to a Lysing Matrix E tube (MP Biomedicals) and mixed with 700 µl phosphate-
- buffered saline (PBS) buffer. The mixture is then shaken at 6.5 m/s for 45 s. After the bead-
- beating, 800 µl of the sample is mixed with 1055 µl of off-board lysis buffer (proteinase K,
- 280 ATL buffer, ACL buffer and nuclease-free water) as recommended by Qiagen. The sample is
- 281 incubated at 68 °C for 15 min for lysis. Nucleic acid purification is performed on the
- 282 QIAsymphony extraction robot using the Complex800\_OBL\_CR22796\_ID 3489 protocol, a
- 283 modified version of the Complex800\_OBL\_V4\_DSP protocol. Purified DNA is eluted in 60
- 284 µl AVE-buffer (Qiagen). DNA purity is assessed using a Nanodrop2000 (Thermo Fisher
- 285 Scientific, USA), and the concentration is measured by Qubit (Thermo Fisher Scientific,
- 286 USA).
- 287 *Metagenome sequencing*
- 288 Libraries for metagenome sequencing are prepared from extracted DNA at the sequencing
- 289 laboratory of the Institute for Molecular Medicine Finland FIMM Technology Centre,
- 290 University of Helsinki (P.O. Box 20, University of Helsinki, Finland) using Illumina
- sequencing, with the aim of producing 3 gigabases of DNA sequence per sample.
- 292 In details, 29 µl of extracted DNA is purified and concentrated by adding an equal volume of
- 293 AMPure XP (Beckman Coulter Life Sciences, Indianapolis, IN, USA). Purification is then
- 294 performed as per the manufacturer's instructions. The purified samples are eluted to 17 µl of
- 295 10 mM Tris-HCl, pH 8.5, and DNA concentrations are determined by Quant-iT PicoGreen
- dsDNA Assay Kit (Thermo Fisher Scientific, Waltham, MA, USA). The samples are
- 297 normalized to a maximum concentration of 3.3 ng/µl, resulting in DNA inputs of 25 ng or
- 298 less.

- 299 Sequencing libraries are prepared according to the Nextera DNA Flex Library Prep Reference
- 300 Guide (v07) (Illumina, San Diego, CA, USA), with the exception that the reaction volumes
- 301 are scaled down to <sup>1</sup>/<sub>4</sub> of the protocol volumes. The libraries are amplified according to the
- 302 protocol with 7 PCR cycles. All the library preparation steps are performed on a Microlab
- 303 STARlet (Hamilton Company, Reno, NV, USA) and Biomek NX [] (Beckman Coulter Life
- 304 Sciences, Indianapolis, IN, USA) liquid handlers running custom scripts.
- 305 DNA concentrations of the finished libraries are determined with Quant-iT PicoGreen dsDNA
- Assay. Libraries are combined into pools containing 240 libraries with 4.5 ng of each library
- 307 using Echo 525 Acoustic Liquid Handler (Beckman Coulter Life Sciences, Indianapolis, IN,
- 308 USA). Library pools are size-selected to a fragment size range between 650 and 900 bp using
- 309 BluePippin (Sage Science Beverly, MA, USA).
- 310 Sequencing is performed with the Illumina NovaSeq system using S4 flow cells with lane
- 311 divider (Illumina, San Diego, CA, USA). Each pool is sequenced on a single lane. Read
- 312 length for the paired-end run is  $2 \times 151$  bp.
- 313 Processing and analysis of sequencing data
- 314 Sequencing data are transferred to a platform for secure storage and analysis of sensitive
- 315 research-related data at the University of Oslo (52). The analysis of metagenomic sequencing
- 316 data is handled in a uniform manner using a customizable workflow manager (53). To
- 317 establish a quality-filtered dataset, standard filters are applied: sequences corresponding to
- adapters used in library preparation, being of low quality (54) and those mapping to the
- human genome (55), with subsequent quality control of filtered sequencing reads (56).
- 320 Taxonomic classification and determination of microbial gene content, including functional
- 321 annotation (e.g. using gene ontology and KEGG databases) will be performed using publicly
- 322 available tools. Abundance measures will be used to calculate taxonomic and functional alpha
- 323 and beta diversity, as well as serving as input for machine learning approaches aimed at
- 324 producing classifiers for high-risk individuals in a data-driven manner. Further metagenome-
- 325 derived measures may include identification of metagenome-assembled genomes, strain-level
- analysis and description of the gut virome.
- 327 <u>Questionnaires</u>
- 328 Two questionnaires are used to collect data on diet, lifestyle and demographic data: a food
- 329 frequency questionnaire (FFQ) and a general lifestyle and demographics questionnaire
- 330 (LDQ). Self-reported dates of questionnaire completion are registered in the project database.

It is made available under a CC-BY-NC 4.0 International license .

331 Returned questionnaires are reviewed manually before scanning and further processing. In

332 cases of low-quality data, participants are contacted for clarification.

333 Assessment of dietary intake

334 Dietary intake is assessed using a semiquantitative, 14-page FFQ, designed to assess the 335 habitual diet during the preceding year. The questionnaire is a modified version of an FFQ 336 developed and validated by the Department of Nutrition, University of Oslo (57–62). The 337 questionnaire has been validated for both energy intake (57-59), intake of macro and 338 micronutrients (57,59,62), as well as selected food items and groups (59-62). The 339 questionnaire includes 23 main questions, covering a total of 256 food items, as well as a free-340 text field for entries of food items not covered by the questionnaire. For each food item 341 (except one on preferred types of fat for cooking), participants are asked to record frequency 342 of consumption, ranging from never/seldom to several times a day, and/or amount, typically 343 as portion size given in various household units (e.g. deciliters, glasses, cups, spoons). In 344 total, there are 249 questions on frequency, 204 on portion size, one on preferences and nine 345 other, mostly related to meal patterns (Additional file 1, supplementary Table 1).

As with any dietary assessment method, the FFQ is prone to errors due to inaccurate reporting

347 and missing answers. Therefore, to mitigate such errors, a standardized framework for how to

348 review and evaluate FFQ quality has been developed. A detailed overview of the framework

349 is given in Additinoal file 2, supplementary Figure 1. In brief, incoming FFQs are reviewed

350 by trained personnel according to a set of predefined criteria. Scanning of questionnaires is

351 performed using the Cardiff TeleForm program (Datascan, Oslo, Norway). The dietary

352 calculation system KBS (short for "Kostberegningssystem"), developed at the Department of

353 Nutrition, University of Oslo, is used to calculate food and nutrient intake. The latest version

of the food database (i.e. AE-18 or newer) will be used, which is largely based on the

355 Norwegian Food Composition Table (63). In line with common practice in nutrition studies,

356 missing answers are imputed as zero intake (59,61,64,65) and observations with extreme

357 energy intake levels in both the upper and lower range will be excluded (66).

358 The main focus of the dietary analyses will be on foods and drinks linked to the risk of CRC

and its precursor lesions, including intakes of alcohol, red and processed meat, wholegrains,

360 foods containing dietary fiber, dairy products and calcium supplements (67). Dietary intake

361 will also be studied holistically by employing various dietary indices such as the 2018 World

It is made available under a CC-BY-NC 4.0 International license .

- 362 Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) index for
- 363 adherence to cancer prevention recommendations (68).
- 364 Assessment of lifestyle and demographic data
- 365 Lifestyle and demographic data are assessed using a four page questionnaire, based on
- 366 questions used in previous national surveys (69,70). Prior to the study start, the questionnaire
- 367 was piloted in a targeted population and adjusted based on feedback from pilot study
- 368 participants. The questionnaire has ten main questions, covering demographic factors
- 369 (education, occupation and marital status), diagnosis of CRC among first-degree relatives,
- 370 presence of chronic bowel disorders and food intolerances, removal of the appendix, mode of
- delivery at birth, smoking and snus (i.e. smokeless tobacco) habits, recent use of medications,
- 372 the past years' physical activity level and lastly use of regular and cultured milk, which is not
- 373 completely covered in the FFQ (see **Table 3** for a detailed overview). In the questions
- 374 concerning smoking and snus habits, participants are asked to recall their current habits,
- including the daily number of cigarettes/snus portions, as well as years since possible
- cessation and total years of use. Questionnaires are scanned and processed using the Cardiff
- 377 TeleForm program (InfoShare, Oslo, Norway).

#### 378 Registry data

- 379 Data collected in the CRCbiome study will be linked to national registries, including the
- 380 Norwegian Prescription Database and the Cancer Registry of Norway, using personal
- 381 identification numbers. Complete data linkages will be undertaken twice during active follow-
- up: after all participants have completed baseline and diagnostic information from follow-up
- 383 colonoscopies is available, and then after the one-year follow-up is completed. In addition,
- 384 linkage to the Cancer Registry of Norway will be performed at least once during the 10 year
- 385 follow-up period.

#### 386 Norwegian Prescription Database

387 The Norwegian Prescription Database (71) will be used to obtain information on medication

- history prior to CRC screening, and during the first year of follow-up. The registry contains
- data on all medications prescribed to Norwegian citizens since 2004. Prescription drugs are
- 390 categorized according to the Anatomical Therapeutic Chemical (ATC) system, a hierarchical
- 391 classification system developed by the WHO (72,73). For each drug, the number of packages
- dispensed, the number of defined daily doses (DDD), the prescription category, and the date
- 393 of dispensing are registered.

It is made available under a CC-BY-NC 4.0 International license .

394 Linkage to the Norwegian Prescription Database enables an in-depth analysis of associations

- between drug use, the gut microbiome and advanced colorectal lesions. Initially, we will
- 396 perform drug-wide association analyses to screen for potential associations, adjusting for key
- 397 covariates. Detected associations will then be examined in detail, including a more refined
- 398 categorization of drug variables, robust covariate adjustments as well as the analysis of timing
- and dose-response relations. Prescription histories will also be used as a proxy for life-long
- 400 burden of chronic diseases.
- 401 Cancer Registry of Norway
- 402 Information on clinicopathological characteristics, cancer therapy, as well as outcomes
- 403 assessed as part of passive follow-up, will be obtained from the Cancer Registry of Norway
- 404 (74). The Cancer Registry of Norway has recorded incident cancer cases on a nationwide
- 405 basis since 1953 and has been shown to have accurate and almost complete ascertainment of
- 406 cases (98.8% for the registration period 2001-2005) (75). According to recent estimates, about
- 407 93% of all cancer cases and  $\geq$ 95% of cancers in the colon and rectum are morphologically
- 408 verified (48). Cancer diagnoses are recorded using the International Classification of
- 409 Diseases, version 10 (ICD-10). Mortality data in the registry are obtained from the Cause of
- 410 Death Registry and coded using the same ICD-10 categories as for the incidence data.
- 411 Data processing and management
- 412 To facilitate project administration, including recruitment and follow-up of participants,
- 413 custom software has been developed. This application communicates with two project
- 414 specific databases (i.e. the BCSN and CRCbiome databases). Only authorized data manager
- 415 personnel have complete access to the datasets. A simplified version of the data generation
- 416 process is depicted in **Figure 2**.
- 417 In line with common practice for linkage with national registries (76), linked data will receive
- 418 unique ID numbers specific to the particular project. Linkage of research data will be
- 419 performed by the data controller. For the metagenome data, which due to its size cannot be
- 420 transferred using ordinary methods, linkage will be performed in-house by an independent
- 421 data manager without access to other parts of the data than those strictly necessary for
- 422 linkage.
- 423 All data collected in the CRCbiome study will be stored and analyzed at a platform for secure
- 424 handling of sensitive research-related data, operated by the University of Oslo (52). Access to
- 425 research data for external investigators, or use outside of the current protocol, will require

- 426 approval from the Norwegian Regional Committee for Medical and Health Research Ethics
- 427 and a data access committee (information available on the project web site (77)). Research
- 428 data are not openly available because of the principles and conditions set out in articles 6 (1)
- 429 (e) and 9 (2) (j) of the General Data Protection Regulation (GDPR).
- 430 Sample size considerations
- 431 The number of participants to include was chosen with the aim of providing adequate power
- 432 for the development of a highly sensitive classification algorithm via data-driven analyses of
- 433 gut metagenomes that will accurately identify FIT-positive individuals in need of clinical
- 434 intervention.
- 435 The classifier will be trained using counts of taxonomic units, signature and genes categorized
- 436 according to gene ontology or pathway membership from metagenomes, FFQ, demographic
- 437 and lifestyle data as input variables, and advanced colorectal lesions as outcome (i.e. group
- 438 group 3 and group 4, **Table 2**). The CRC risk classification will be done using machine
- 439 learning algorithms suited to metagenome data, such as lasso regression (78), support-vector
- 440 machines (79), random forests (80), multi-layer perception neural networks (81) and scalable
- 441 tree boosting (82) algorithms. Evaluation of the classifier will be conducted in a leave-out test
- 442 set. As outlined below, we believe that with sufficient sample size, development of a classifier
- 443 with a sensitivity of 0.95 is achievable in the training set, being within the range of published
- 444 reports (30,33).
- 445 With a projected classifier sensitivity of 0.95 and a minimally acceptable sensitivity of 0.8, at
- 446 80% power and 95% confidence level, 50 participants with advanced colorectal lesions are
- 447 required in the test set (83). Classifier specificity in the setting of FIT-positive individuals will
- 448 have a lower requirement, and we therefore set the expected classifier specificity to 0.75 and a
- 449 minimally acceptable specificity of 0.6, thus requiring 100 participants with normal findings
- 450 in the test set. Based on initial recruitment, we expect a participation rate of 58%, with 26% of
- 451 participants having findings of advanced lesions or CRC (Table 2). By inviting 2,700 FIT-
- 452 positive BCSN participants, and splitting the training and test sets 80/20, a projected number
- 453 of 1,253 and 313 participants will constitute the training and test sets, respectively, which will
- 454 include adequate numbers of participants with both advanced colorectal lesions and normal
- 455 findings in the test set. With this sample size, we will also be able to perform stratified
- 456 analyses.

It is made available under a CC-BY-NC 4.0 International license .

#### 457 **Discussion**

458 CRC remains a major public health challenge with substantial personal and societal costs 459 (22). Screening is an effective measure to reduce disease burden (22). However, current 460 screening methods suffer from limitations, limiting the number of preventable cases. 461 Innovative use of currently available methods represents a promising avenue for 462 improvements in CRC prevention (22). The current study is designed to contribute to the 463 development of microbial biomarkers, using metagenome sequencing and comprehensive 464 questionnaire and registry data for improved detection of advanced lesions and CRC in a FIT-465 positive population. The CRCbiome study is unique in that it uses data from the screening

466 population to develop relevant biomarkers.

467 The idea of using microbial biomarkers to increase the performance of CRC screening has

468 received increased attention with the adoption of high-throughput characterization of the gut

469 microbiome. Ideally, combining microbial biomarkers with FIT testing could achieve the

470 sensitivity of direct visualization methods and the uptake of non-invasive fecal tests. Several

471 studies have demonstrated improved ability to discriminate individuals with healthy colons

472 from those with advanced neoplasia when adding microbial biomarkers in the prediction

473 model, more so for carcinoma (area under the curve (AUC) of 0.87-0.97 (30,33,34)) than

474 adenoma (AUC of 0.76 (33)). Despite great promise, these studies have typically been limited

475 by small sample sizes (30,32–34), cross-sectional designs (30–34), use of suboptimal or low-

476 resolution methods to study the gut-microbiome (30–33) and lack of data on important

477 confounders (30–34). The CRCbiome study seeks to address several of these shortcomings.

478 Major strengths of the CRCbiome study include its large sample size and prospective nature,

479 use of state of the art methodology for studying the gut microbiome and access to detailed

480 information on likely confounders of the relationship between the gut-microbiome and

481 advanced colorectal lesions. A further strength of the study is in its organization and logistics

482 structure, being nested within the BCSN. The immediate availability of clinically verified

483 outcome data, via follow-up colonoscopies and cancer registry data, allow for prospective

484 investigations on multiple outcomes relevant to the screening population (e.g. polyp

recurrence). Access to comprehensive high-quality data on diet and lifestyle, including

486 complete prescription histories, also enables the investigation of the predictive performance of

487 more broad classifiers, laying the ground for personalized screening strategies, including risk-

488 stratified approaches.

It is made available under a CC-BY-NC 4.0 International license .

489 With a study population solely consisting of FIT positive participants, the projected number

490 of individuals with high-risk lesions or CRC is relatively high (about 409 (26%), group 3 and

491 4, **Table 2**), thereby increasing the power to achieve accurate classification of advanced

492 colorectal neoplasms. Still, whether findings in this population extends to cases missed by

493 FIT testing is unknown.

494 Collection of follow-up samples at 2 and 12-months post colonoscopy represents an extension

495 of the cross-sectional design of most prior studies, shedding light on the development of the

496 gut microbiome following colonoscopy with or without removal of CRC precursor lesions.

497 While there are examples of shifts in microbial profiles following colonoscopy, the gut

498 microbiome typically reverts to the initial state within weeks (84). Deviations from re-

499 establishment of the gut microbiome both in the medium and long term have the potential for

500 causal interpretations.

501 The study also has some limitations. Exclusive selection of FIT positive participants may

502 limit the generalizability of the findings to those with bleeding neoplastic lesions.

503 Consequently, improvements in diagnostic performance may be limited to specificity, and

thus the ability to correctly classify healthy individuals. However, since lesions tend to bleed

505 intermittently (85) and the study aims to identify potential causal pathways, we consider it

506 likely that the identified biomarker also may have improved sensitivity in the screening

507 population as a whole.

508 A further limitation is the lack of information on fecal metrics such as the Bristol stool scale,

509 which has been shown to be an important determinant of microbiota richness and variance

510 (86). However, variation in microbiome profile due to stool consistency could likely be

511 explored by use of gastrointestinal symptoms as a surrogate, data on which is available in the

512 BCSN database.

513 Lastly, lack of follow-up data on diet and lifestyle may complicate the interpretation of

514 microbial changes following colonoscopy. Even though prior studies in comparable study

515 populations show that potential changes in diet and lifestyle following screening are modest

516 (87,88), caution in interpretation of follow-up samples is warranted.

517 The CRCbiome study represents a valuable source of data for further research. An example is

518 access to complete prescription histories from the Norwegian Prescription Database that

519 enables in-depth analyses of associations between a broad range of medications, microbial

520 features and neoplasia risk, both during short and long-term follow-up. The fecal samples

It is made available under a CC-BY-NC 4.0 International license .

- 521 collected are also biobanked and can be used for other purposes beside the study aims of the
- 522 current protocol. For instance, in addition to metagenome sequencing, the fecal samples can
- 523 potentially be used for other omics analyses, such as transcriptome and metabolome analysis.
- 524 All tissue specimens removed during colonoscopy are also available to the project, enabling
- 525 in-depth molecular profiling.

#### 526 Conclusion

- 527 The CRCbiome study investigates the role of the gut microbiome, and its interactions with
- 528 host factors, diet and lifestyle, in early stage colorectal carcinogenesis. Information obtained
- 529 from this project will guide the development of a microbial biomarker for accurate detection
- 530 of advanced colorectal lesions. By performing biomarker discovery within a screening
- 531 population, the generalizability of the findings to future screening cohorts is likely to be high.

It is made available under a CC-BY-NC 4.0 International license .

## 532 List of abbreviations

- 533 AICR: American Institute for Cancer Research
- 534 ATC: Anatomical Therapeutic Chemical
- 535 AUC: area under the curve
- 536 BCA: bovine serum albumin
- 537 BCSN: Bowel Cancer Screening in Norway
- 538 Bp: base pair
- 539 CRC: colorectal cancer
- 540 CRN: Cancer Registry of Norway
- 541 CT: computed tomography
- 542 DDD: defined daily doses
- 543 DNA: deoxyribonucleic acid
- 544 DPIA: Data Processing Impact Assessment
- 545 FFQ: food frequency questionnaire
- 546 FIMM: Institute for Molecular Medicine Finland
- 547 FIT: fecal immunochemical test
- 548 FU: follow-up
- 549 gFOBT: guaiac-based fecal occult blood test
- 550 ICD: International Classification of Diseases
- 551 KBS: Kostberegningssystem ("Dietary calculation system")
- 552 KEGG: Kyoto Encyclopedia of Genes and Genomes
- 553 LDQ: lifestyle and demographic questionnaire
- 554 NCT: National Clinical Trial
- 555 NorPD: Norwegian Prescription Database
- 556 NSAIDs: non-steroid anti-inflammatory drugs

- 557 PCR: polymerase chain reaction
- 558 PBS: phosphate-buffered saline
- 559 SCFA: short chain fatty acid
- 560 STROBE: Strengthening the Reporting of Observational Studies in Epidemiology
- 561 WCRF: World Cancer Research Fund
- 562 WHO: World Health Organization

It is made available under a CC-BY-NC 4.0 International license .

# 563 **Declarations**

564	Ethics approval and consent to participate
565	The CRCbiome study is approved by the Norwegian Regional Committees for Medical and
566	Health Research Ethics (Approval no.: 63148). Written informed consent to participate has
567	been obtained from all participants at study enrollment. All biological materials are stored in a
568	biobank at Oslo University Hospital.
569	
570	Consent for publication
571	Not applicable.
572	
573	Availability of data and materials
574	Due to the principles and conditions set out in articles 6 (1) (e) and 9 (2) (j) of the General
575	Data Protection Regulation (GDPR), research data generated in the CRCbiome study are not
576	openly available. Further information on access to CRCbiome data can be found on the
577	project web site (77)).
578	
579	Competing interests
580	There are no competing interests.
581	
582	Funding
583	This project would not have been possible without funding from the Norwegian Cancer
584	Society, the Research Council of Norway and the South Eastern Norway Regional Health
585	Authority.
586	
587	Authors' contributions
588	ASK and EB (Birkeland) had the main responsibility for writing the manuscript.
589	PB and TBR are the principal investigators.
590	All authors contributed to the study design and protocol.
591	All authors contributed to the writing and approval of the final manuscript

It is made available under a CC-BY-NC 4.0 International license .

## 592 Acknowledgements

- 593 We would like to aknowledge the devoted secretaries, nurses and doctors at Bærum and Moss
- bospital, and the biomedical laboratory scientists at Oslo University Hospital for their
- 595 contributions to this study. We would also like to thank the personnel involved in sequencing
- all CRCbiome samples at the Sequencing laboratory of Institute for Molecular Medicine
- 597 Finland FIMM Technology Centre, University of Helsinki. Lastly, we would like to thank
- 598 each study participoant, as well as all collaborative partners, technicians and students that
- 599 have, and will, contribute to this study.

It is made available under a CC-BY-NC 4.0 International license .

## 600 **References**

601 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer 602 statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 603 cancers in 185 countries. CA Cancer J Clin. 2018;68. 604 2. Ouakrim DA, Pizot C, Boniol M, Malvezzi M, Boniol M, Negri E, Bota M, Jenkins 605 MA, Bleiberg H, Autier P. Trends in colorectal cancer mortality in Europe: 606 Retrospective analysis of the WHO mortality database. BMJ. 2015;351:1-10. 607 3. Safiri S, Sepanlou SG, Ikuta KS, Bisignano C, Salimzadeh H, Delavari A, Ansari R, 608 Roshandel G, Merat S, Fitzmaurice C, et al. The global, regional, and national burden 609 of colorectal cancer and its attributable risk factors in 195 countries and territories, 610 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 611 Gastroenterol Hepatol. 2019:4:913-33. 612 4. Danckert B, Ferlay J, Engholm G, Hansen HL, Johannesen TB, Khan S, Køtlum JE, 613 Ólafsdóttir E, Schmidt LKH, Virtanen A and Storm HH. Danckert B, Ferlay J, 614 Engholm G, Hansen HL, Johannesen TB, Khan S, Køtlum JE, Ólafsdóttir E, Schmidt 615 LKH VA and SH. NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival 616 in the Nordic Countries. Version 8.2. 2019. 617 5. Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, 618 Mariotto A, Lewis DR, Chen HS, Feuer EJ CK (eds). SEER Cancer Statistics Review, 619 1975-2017, National Cancer Institute. 2020. Available from: 620 https://seer.cancer.gov/csr/1975 2017/, based on November 2019 SEER data 621 submission, posted to the SEER web site, April 2020. 622 6. Sung H, Siegel RL, Rosenberg PS, Jemal A, Emerging cancer trends among young 623 adults in the USA: analysis of a population-based cancer registry. Lancet Public Heal. 624 2019;4. 625 7. Araghi M, Soerjomataram I, Bardot A, Ferlay J, Cabasag CJ, Morrison DS, De P, 626 Tervonen H, Walsh PM, Bucher O, et al. Changes in colorectal cancer incidence in 627 seven high-income countries: a population-based study. Lancet Gastroenterol Hepatol. 628 2019;4:511-8. 629 8. Leggett B, Whitehall V. Role of the Serrated Pathway in Colorectal Cancer 630 Pathogenesis. Gastroenterology Elsevier Inc.; 2010;138:2088–100. 631 http://dx.doi.org/10.1053/j.gastro.2009.12.066 632 9. Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet 633 (London, England) Elsevier Ltd; 2019;394:1467-80. 634 http://www.ncbi.nlm.nih.gov/pubmed/31631858 635 10. Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW, García FAR, 636 Gillman MW, Harper DM, Kemper AR, Krist AH, et al. Screening for colorectal 637 cancer: US preventive services task force recommendation statement. JAMA - J Am 638 Med Assoc. 2016;315:2564-75. 639 11. Segnan N, Patnick J, von Karsa L EC. European Guidelines for Quality Assurance in 640 Colorectal Cancer Screening and Diagnosis - First Edition. Luxembourg: Office for 641 Official Publications of the European Communities; 2010. 642 12. Ebell MH, Thai TN, Royalty KJ. Cancer screening recommendations: An international

643 644		comparison of high income countries. Public Health Rev. Public Health Reviews; 2018;39:1–19.
645 646 647	13.	Sung JJY, Ng SC, Chan FKL, Chiu HM, Kim HS, Matsuda T, Ng SSM, Lau JYW, Zheng S, Adler S, et al. An updated Asia Pacific Consensus Recommendations on colorectal cancer screening. Gut. 2015;64:121–32.
648 649 650 651	14.	Atkin W, Wooldrage K, Parkin DM, Kralj-Hans I, MacRae E, Shah U, Duffy S, Cross AJ. Long term effects of once-only flexible sigmoidoscopy screening after 17 years of follow-up: the UK Flexible Sigmoidoscopy Screening randomised controlled trial. Lancet. 2017;389:1299–311. http://dx.doi.org/10.1016/S0140-6736(17)30396-3
652 653 654	15.	Schoen R, Pinsky P, Weissfeld J, Yokochi L, Church T, Laiyemo A, Bresalier R, Andriole G, Buys S, Crawford E, et al. Colorectal-Cancer Incidence and Mortality with Screening Flexible Sigmoidoscopy. N Engl J Med. 2012;366:2345–57.
655 656 657 658	16.	Segnan N, Armaroli P, Bonelli L, Risio M, Sciallero S, Zappa M, Andreoni B, Arrigoni A, Bisanti L, Casella C, et al. Once-only sigmoidoscopy in colorectal cancer screening: Follow-up findings of the italian randomized controlled trial - SCORE. J Natl Cancer Inst. 2011;103:1310–22.
659 660 661 662	17.	Holme Ø, Løberg M, Kalager M, Bretthauer M, Hernán MA, Aas E, Eide TJ, Skovlund E, Schneede J, Tveit KM, et al. Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: A randomized clinical trial. JAMA - J Am Med Assoc. 2014;312:606–15.
663 664 665	18.	Mandel J, Bond J, Church T, Snover D, Bradley M, Schuman L, Ederer F. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med. 1993;
666 667 668	19.	Kronborg O, Fenger C, Olsen J, Jørgensen OD, Søndergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet Elsevier; 1996;348:1467–71. https://doi.org/10.1016/S0140-6736(96)03430-7
669 670 671	20.	Lindholm E, Brevinge H, Haglind E. Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer. Br J Surg. England; 2008;95:1029–36.
672 673 674 675	21.	Hardcastle JD, Chamberlain JO, Robinson MHE, Moss SM, Amar SS, Balfour TW, James PD, Mangham CM. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet Elsevier; 1996;348:1472–7. https://doi.org/10.1016/S0140-6736(96)03386-7
676 677 678	22.	Ladabaum U, Dominitz JA, Kahi C, Schoen RE. Strategies for Colorectal Cancer Screening. Gastroenterology Elsevier, Inc; 2020;158:418–32. https://doi.org/10.1053/j.gastro.2019.06.043
679 680 681	23.	Schreuders EH, Ruco A, Rabeneck L, Schoen RE, Sung JJY, Young GP, Kuipers EJ. Colorectal cancer screening: A global overview of existing programmes. Gut. 2015;64:1637–49.
682 683 684 685	24.	Haug U, Kuntz KM, Knudsen AB, Hundt S, Brenner H. Sensitivity of immunochemical faecal occult blood testing for detecting left-vs right-sided colorectal neoplasia. Br J Cancer. Nature Publishing Group; 2011;104:1779–85. http://dx.doi.org/10.1038/bjc.2011.160

686 687 688 689	25.	Holme Ø, Løberg M, Kalager M, Bretthauer M, Hernán MA, Aas E, Eide TJ, Skovlund E, Lekven J, Schneede J, et al. Long-term effectiveness of sigmoidoscopy screening on colorectal cancer incidence and mortality in women and men: A randomized trial. Ann Intern Med. 2018;168:775–82.
690 691 692	26.	Brenner H, Qian J, Werner S. Variation of diagnostic performance of fecal immunochemical testing for hemoglobin by sex and age: Results from a large screening cohort. Clin Epidemiol. 2018;10:381–9.
693 694	27.	Tilg H, Adolph TE, Gerner RR, Moschen AR. The Intestinal Microbiota in Colorectal Cancer. Cancer Cell. Elsevier Inc.; 2018;33:954–64.
695 696 697	28.	Kostic AD, Gevers D, Pedamallu CS, Michaud M, Duke F, Earl AM, Ojesina AI, Jung J, Bass AJ, Tabernero J, et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 2012;22:292–8.
698 699 700 701 702 703 704	29.	Castellarin M, Warren R, Freeman J, Dreolini L, Krzywinski M, Strauss J, Barnes R, Watson P, Allen-Vercoe E, Moore RA, et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res 2012;22:299–306. http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L364 186952%5Cnhttp://genome.cshlp.org/content/22/2/299.full.pdf+html%5Cnhttp://dx.doi .org/10.1101/gr.126516.111%5Cnhttp://sfx.library.uu.nl/utrecht?sid=EMBASE&issn= 10889051&id=doi:10
705 706	30.	Zackular JP, Rogers MAM, Ruffin MT, Schloss PD. The human gut microbiome as a screening tool for colorectal cancer. Cancer Prev Res. 2014;7:1112–21.
707 708 709 710	31.	Guo S, Li L, Xu B, Li M, Zeng Q, Xiao H, Xue Y, Wu Y, Wang Y, Liu W, et al. A simple and novel fecal biomarker for colorectal cancer: Ratio of Fusobacterium nucleatum to probiotics populations, based on their antagonistic effect. Clin Chem. 2018;64:1327–37.
711 712 713	32.	Liang Q, Chiu J, Chen Y, Huang Y, Higashimori A, Fang J, Brim H, Ashktorab H, Chien Ng S, Ng SSM, et al. Fecal bacteria act as novel biomarkers for noninvasive diagnosis of colorectal cancer. Clin Cancer Res. 2017;23:2061–70.
714 715 716	33.	Baxter NT, Ruffin MT, Rogers MAM, Schloss PD. Microbiota-based model improves the sensitivity of fecal immunochemical test for detecting colonic lesions. Genome Med Genome Medicine; 2016;8:1–10. http://dx.doi.org/10.1186/s13073-016-0290-3
717 718 719	34.	Zeller G, Tap J, Voigt AY, Sunagawa S, Kultima JR, Costea PI, Amiot A, Böhm J, Brunetti F, Habermann N, et al. Potential of fecal microbiota for early stage detection of colorectal cancer. Mol Syst Biol. 2014;10:766.
720 721 722	35.	Ahn J, Sinha R, Pei Z, Dominianni C, Wu J, Shi J, Goedert JJ, Hayes RB, Yang L. Human gut microbiome and risk for colorectal cancer. J Natl Cancer Inst. 2013;105:1907–11.
723 724 725	36.	Vogtmann E, Hua X, Zeller G, Sunagawa S, Voigt AY, Hercog R, Goedert JJ, Shi J, Bork P, Sinha R. Colorectal cancer and the human gut microbiome: Reproducibility with whole-genome shotgun sequencing. PLoS One. 2016;11:1–13.
726 727 728	37.	Feng Q, Liang S, Jia H, Stadlmayr A, Tang L, Lan Z, Zhang D, Xia H, Xu X, Jie Z, et al. Gut microbiome development along the colorectal adenoma-carcinoma sequence. Nat Commun. 2015;6.

729 730 731	38.	Yu J, Feng Q, Wong SH, Zhang D, Yi Liang Q, Qin Y, Tang L, Zhao H, Stenvang J, Li Y, et al. Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer. Gut. 2017;66:70–8.
732 733 734	39.	Hale VL, Chen J, Johnson S, Harrington SC, Yab TC, Smyrk TC, Nelson H, Boardman LA, Druliner BR, Levin TR, et al. Shifts in the fecal microbiota associated with adenomatous polyps. Cancer Epidemiol Biomarkers Prev. 2017;26:85–94.
735 736 737	40.	Rothschild D, Weissbrod O, Barkan E, Kurilshikov A, Korem T, Zeevi D, Costea PI, Godneva A, Kalka IN, Bar N, et al. Environment dominates over host genetics in shaping human gut microbiota. Nat Publ Gr. Nature Publishing Group; 2018;
738 739 740	41.	Song M, Chan AT, Sun J. Influence of the Gut Microbiome, Diet, and Environment on Risk of Colorectal Cancer. Gastroenterology Elsevier, Inc; 2020;158:322–40. https://doi.org/10.1053/j.gastro.2019.06.048
741 742 743 744	42.	Song M, Chan AT. Environmental Factors, Gut Microbiota, and Colorectal Cancer Prevention Clinical Gastroenterology and Hepatology. The American Gastroenterological Association; 2019. 275–289 p. https://doi.org/10.1016/j.cgh.2018.07.012
745 746 747 748	43.	Scott AJ, Alexander JL, Merrifield CA, Cunningham D, Jobin C, Brown R, Alverdy J, O'Keefe SJ, Gaskins HR, Teare J, et al. International Cancer Microbiome Consortium consensus statement on the role of the human microbiome in carcinogenesis. Gut. 2019;68:1624–32.
749 750 751 752 753	44.	Thomas AM, Manghi P, Asnicar F, Pasolli E, Armanini F, Zolfo M, Beghini F, Manara S, Karcher N, Pozzi C, et al. Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradation. Nat Med Springer US; 2019;25:667–78. http://dx.doi.org/10.1038/s41591-019-0405-7
754 755 756 757	45.	Wirbel J, Pyl PT, Kartal E, Zych K, Kashani A, Milanese A, Fleck JS, Voigt AY, Palleja A, Ponnudurai R, et al. Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer. Nat Med Springer US; 2019;25:679–89. http://dx.doi.org/10.1038/s41591-019-0406-6
758 759 760 761	46.	Randel KR, Schult AL, Botteri E, Hoff G, Bretthauer M, Ursin G, Natvig E, Berstad P, Jørgensen A, Sandvei PK, et al. Colorectal cancer screening with repeated fecal immunochemical test versus sigmoidoscopy: baseline results from a randomized trial. Gastroenterology. United States; 2020;
762 763	47.	Norwegian Institute of Public Health (NIPH). Norwegian Prescription Database (NorPD) [cited 2020 Nov 5]. https://www.fhi.no/en/hn/health-registries/norpd/
764 765	48.	Cancer Registry of Norway. Cancer in Norway 2019 - Cancer incidence, mortality, survival and prevalence in Norway. Oslo; 2020.
766 767 768 769	49.	Vandenbroucke JP, Von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and elaboration. PLoS Med. 2007;4:1628–54.
770 771	50.	Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M, Blettner M, et al. S1,trengthening the Reporting of

772 773		Observational Studies in Epidemiology (STROBE): Explanation and elaboration. Int J Surg Elsevier Ltd; 2014;12:1500–24. http://dx.doi.org/10.1016/j.ijsu.2014.07.014
774 775 776 777	51.	Bharucha T, Oeser C, Balloux F, Brown JR, Carbo EC, Charlett A, Chiu CY, Claas ECJ, de Goffau MC, de Vries JJC, et al. STROBE-metagenomics: a STROBE extension statement to guide the reporting of metagenomics studies. Lancet Infect Dis Elsevier Ltd; 2020;3099:1–10. http://dx.doi.org/10.1016/S1473-3099(20)30199-7
778 779	52.	University of Oslo (UiO). About TSD [cited 2020 Dec 14]. https://www.uio.no/english/services/it/research/sensitive-data/about/index.html
780 781	53.	Köster J, Rahmann S. Snakemake - A scalable bioinformatics workflow engine. Bioinformatics. 2018;34:3600.
782 783	54.	Bolger AM, Lohse M, Usadel B. Trimmomatic: A flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30:2114–20.
784 785	55.	Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012;9:357–9.
786 787	56.	Ewels P, Magnusson M, Lundin S, Käller M. MultiQC: Summarize analysis results for multiple tools and samples in a single report. Bioinformatics. 2016;32:3047–8.
788 789 790	57.	Andersen LF, Solvoll K, Johansson LRK, Salminen I, Aro A, Drevon CA. Evaluation of a food frequency questionnaire with weighed records, fatty acids, and alphatocopherol in adipose tissue and serum. Am J Epidemiol. 1999;150:75–87.
791 792 793	58.	Andersen LF, Tomten H, Haggarty P, Løvø A, Hustvedt BE. Validation of energy intake estimated from a food frequency questionnaire: A doubly labelled water study. Eur J Clin Nutr. 2003;57:279–84.
794 795 796 797	59.	Carlsen MH, Lillegaard IT, Karlsen A, Blomhoff R, Drevon CA, Andersen LF. Evaluation of energy and dietary intake estimates from a food frequency questionnaire using independent energy expenditure measurement and weighed food records. Nutr J. 2010;9:1–9.
798 799 800	60.	Andersen LF, Veierød MB, Johansson L, Sakhi A, Solvoll K, Drevon CA. Evaluation of three dietary assessment methods and serum biomarkers as measures of fruit and vegetable intake, using the method of triads. Br J Nutr. 2005;93:519–27.
801 802 803 804	61.	Carlsen MH, Karlsen A, Lillegaard ITL, Gran JM, Drevon CA, Blomhoff R, Andersen LF. Relative validity of fruit and vegetable intake estimated from an FFQ, using carotenoid and flavonoid biomarkers and the method of triads. Br J Nutr. 2011;105:1530–8.
805 806 807 808	62.	Brunvoll SH, Thune I, Frydenberg H, Flote VG, Bertheussen GF, Schlichting E, Bjerve KS, Hjartåker A. Validation of repeated self-reported n-3 PUFA intake using serum phospholipid fatty acids as a biomarker in breast cancer patients during treatment. Nutr J. Nutrition Journal; 2018;17:1–12.
809 810	63.	Norwegian Food Safety Authority. Norwegian Food Composition Database 2019 [cited 2020 Jun 16]. www.matvaretabellen.no
811 812 813	64.	Johansson I, Hallmans G, Wikman Å, Biessy C, Riboli E, Kaaks R. Validation and calibration of food-frequency questionnaire measurements in the Northern Sweden Health and Disease cohort. Public Health Nutr. 2002;5:487–96.

814 815 816	65.	Holmberg L, Ohlander EM, Byers T, Zack M, Wolk A, Bruce Å, Bergstrom R, Bergkvist L, Adami HO. A Search for Recall Bias in a Case-Control Study of Diet and Breast Cancer. Int J Epidemiol. 1996;25:235–44.
817 818	66.	Willett W. Nutritional epidemiology. Oxford; New York: Oxford University Press; 2013.
819 820 821 822	67.	World Cancer Research Fund/American Institute for Cancer Research. Diet, nutrition, physical activity and colorectal cancer Continuous Update Project. 2018. https://www.wcrf.org/sites/default/files/Colorectal-cancer-report.pdf%0Ahttps://www.wcrf.org/sites/default/files/Oesophageal-cancer-report.pdf
823 824 825 826	68.	Shams-White MM, Brockton NT, Mitrou P, Romaguera D, Brown S, Bender A, Kahle LL, Reedy J. Operationalizing the 2018 World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) Cancer Prevention Recommendations: A Standardized Scoring System. Nutrients. 2019;11:1572.
827 828 829 830	69.	Markussen MS, Veierod MB., Kristiansen AL, Ursin G, Andersen LF. Dietary patterns of women aged 50-69 years and associations with nutrient intake, sociodemographic factors and key risk factors for non-communicable diseases. Public Health Nutr. 2016;19:2024–32.
831 832 833 834	70.	Knudsen MD, Berstad P, Hjartåker A, Gulichsen EH, Hoff G, De Lange T, Bernklev T, Botteri E. Lifestyle predictors for non-participation and outcome in the second round of faecal immunochemical test in colorectal cancer screening. Br J Cancer. 2017;117:461–9.
835	71.	Folkehelseinstituttet. Reseptregisteret 2012-2016. 2017.
836 837	72.	WHO Collaborating Centre for Drug Statistics Methodology. Structure and principles [cited 2020 Sep 28]. https://www.whocc.no/atc/structure_and_principles/
838 839	73.	WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2020 [cited 2020 Sep 28]. https://www.whocc.no/atc_ddd_index/
840 841	74.	Cancer Registry of Norway. Cancer in Norway 2018 - Cancer incidence, mortality, survival and prevalence in Norway. Oslo; 2019.
842 843 844	75.	Larsen IK, Smastuen M, Johannesen TB, Langmark F, Parkin DM, Bray F, Moller B. Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer. England; 2009;45:1218–31.
845 846 847 848	76.	Norwegian Institute of Public Health (NIPH). Access to data from the Norwegian Prescription Database [cited 2020 Jun 19]. https://www.fhi.no/en/hn/health- registries/norpd/Access-data-norpd/#legal-requirements-for-the-disclosure-of-data- from-the-norpd
849 850 851 852	77.	Cancer Registry of Norway. The microbiome as a colorectal cancer screening biomarker [cited 2020 Sep 29]. https://www.kreftregisteret.no/en/Research/Projects/microbiota-and-lifestyle-in- colorectal-cancer-screeing/
853 854	78.	Tibshirani R. Regression Shrinkage and Selection Via the Lasso doi:10.1111/j.2517-6161.1996.tb02080.x. J R Stat Soc Ser B. 1996;58:267–88.
855	79.	Cortes C, Vapnik V. Support-vector networks. Mach Learn. 1995;

It is made available under a CC-BY-NC 4.0 International license .

0.00 $0.00$ Dicilian L. Random forests. Mach Learn. 2001,1 1.	1-122.
---	--------

- 857 81. Haykin S. Neural Networks and Learning Machines. Third Edit. Pearson Prentice Hall;
  858 2009.
- 859 82. Chen T, Guestrin C. XGBoost: A Scalable Tree Boosting System. Proc 22nd ACM
  860 SIGKDD Int Conf Knowl Discov Data Min. 2016;
- 861 83. Stark M, Zapf A. Sample size calculation and re-estimation based on the prevalence in a single-arm confirmatory diagnostic accuracy study. Stat Methods Med Res. 2020;
- 863 84. Nagata N, Tohya M, Fukuda S, Suda W, Nishijima S, Takeuchi F, Ohsugi M,
  864 Tsujimoto T, Nakamura T, Shimomura A, et al. Effects of bowel preparation on the
  865 human gut microbiome and metabolome. Sci Rep. 2019;9:1–8.
- 866 85. Ahlquist DA, McGill DB, Fleming JL, Schwartz S, Wieand HS, Rubin J, Moertel CG.
  867 Patterns of occult bleeding in asymptomatic colorectal cancer. Cancer. 1989;63:1826–
  868 30.
- 869 86. Hannelore D. Diet and the gut microbiome: from hype to hypothesis. Br J Nutr.
  870 2020;1–24.
- 87. Berstad P, Løberg M, Larsen IK, Kalager M, Holme Ø, Botteri E, Bretthauer M, Hoff
  872 G. Long-term lifestyle changes after colorectal cancer screening: Randomised
  873 controlled trial. Gut. 2015;64:1268–76.
- 874 88. Knudsen MD, Hjartåker A, Olsen MKE, Hoff G, De Lange T, Bernklev T, Berstad P.
  875 Changes in health behavior 1 year after testing negative at a colorectal cancer
  876 screening: A randomized-controlled study. Eur J Cancer Prev. 2018;27:316–22.
- 877 89. Hassan C, Quintero E, Dumonceau JM, Regula J, Brandão C, Chaussade S, Dekker E,
  878 Dinis-Ribeiro M, Ferlitsch M, Gimeno-García A, et al. Post-polypectomy colonoscopy
  879 surveillance: European Society of Gastrointestinal Endoscopy (ESGE) Guideline.
  880 Endoscopy. 2013;45:842–51.

881

It is made available under a CC-BY-NC 4.0 International license .

# Tables, figure titles and legends

It is made available under a CC-BY-NC 4.0 International license .

# **Tables**

	•
Inclusion criteria	
BCSN	Aged 50-74 years old in 2012
	Resident in selected municipalities in South-East Norway (Østfold, parts of
	Akershus and parts of Buskerud)
CRCbiome	FIT positive test (i.e. hemoglobin >15 mcg/g feces) and invited to a follow-up
	colonoscopy
Exclusion criteria	
BCSN	Death <sup>1</sup>
	Moving out of the area <sup>1</sup>
	Reaching the upper age limit <sup>1</sup>
	Diagnosed with CRC <sup>1</sup>
CRCbiome	Not attending screening colonoscopy
	Low DNA concentration
	Low sequencing yield (<2 gigabases)

Table 1. Inclusion and exclusion criteria in the BCSN trial and CRCbiome study.

<sup>1</sup>*Exclusion criteria apply for individuals who died, moved out of the area, reached the upper age limit, or were diagnosed with CRC before they were due for invitation.* 

It is made available under a CC-BY-NC 4.0 International license .

	Demonstrate and
<u>Colonoscopy result</u>	Percentages
FIT+, no colonoscopy	3.6
Group 1	
Negative	11.2
Polyp without histology <sup>2</sup>	2.4
Non neoplastic findings	18.2
Group 2	
Non-advanced serrated lesions <sup>3</sup>	6.4
Non-advanced adenomas (<3)	23.6
Non-advanced adenomas (≥3)	8.4
Group 3	
Advanced serrated lesions <sup>4</sup>	4.4
Advanced adenoma <sup>5</sup>	18.1
Group 4	
$CRC^{6}$	3.6

Table 2. Main outcomes of the screening colonoscopy among CRCbiome participants with preliminary distribution in percentages as of November 2020.

 $^{1}An$  extended version of this table, with colonoscopy result by FIT round, is shown in Additional file 1 (Supplementary table

2). In cases of multiple findings, participants are allocated to the most severe group. Numbers will therefore add up to 100%. <sup>2</sup>Polyps lost during colonoscopy or where the endoscopist considers biopsy unnescessary, for example hyperplastic polyps in the rectum.

 $^{3}$ Includes hyperplastic polyps with size <10 mm and sessile serrated lesions without dysplasia and size <10 mm.

<sup>4</sup>Defined as any serrated lesions with size  $\geq 10$  mm or dysplasia.

<sup>5</sup>Defined as any adenoma with either villous histology ( $\geq$ 25% villous components), high-grade dysplasia or polyp size greater than or equal to 10 mm (89). <sup>6</sup>Defined as presence of adenocarcinoma arising from the colon or rectum. Collectively, advanced adenoma or CRC are

referred to as advanced neoplasia (89).

It is made available under a CC-BY-NC 4.0 International license .

	1 0× 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Time points <sup>1</sup>			s <sup>1</sup>
		Baseline	2 months	12 months	10 years
Clinical data					
Medical history	Prior colonoscopies and CT colonographies, comorbidities (3 items), drug use (6 items), gastrointestinal symptoms (9 items), smoking habits (1 item) and body weight and height	x			
Screening specific data	FIT value, endoscopic findings, histopathology and clinical diagnoses, type of procedure and bowel preparation used, degree of bowel cleansing, intubation level, duration of colonoscopy, use of sedation or analgesia, reason for ending the examination, if necessary, and recommended surveillance	Х			
Fecal samples	Gut microbiome profile including taxonomic and				
r cear samples	functional profiles	Х	Х	х	
Questionnaires	runctional profiles				
Lifestyle and demographics (LDQ) Diet (FFQ)	Demographic factors (i.e. national background, marital status, education and occupation), smoking and snus habits (up to 5 questions each), physical activity (hours spent on physical activity of light, moderate and high intensity per week and presence of chronic diseases restricting ability of being physically active), use of regular and cultured milk (two frequency questions), mode of delivery at birth, removal of the appendix, recent use of medications (i.e. antibiotic and antacid usage the last three months), presence of chronic bowel disorders and food intolerances (closed and open format questions) and presence of CRC among first-degree relatives Energy intake, intake of macro and micronutrients,	x			
Diet (FFQ)	Energy intake, intake of macro and micronutrients, frequency and/or amounts of 256 foods and drinks consumed <sup>2</sup> , dietary patterns, including meal pattern, body weight and height	Х			
Registry data					
Cancer registry	Cancer incidence and mortality, clinicopathological characteristics, information on treatment regimens	х		х	x
Prescriptions database	Complete prescription history since 2004	x		x	

and last colonoscopy, respectively.

<sup>2</sup>A complete overview of the food items included in the FFQ is given in Additional file 1 (Supplementary table 1).

It is made available under a CC-BY-NC 4.0 International license .

# Figure titles and legends

**Figure 1. Flowchart of the CRCbiome study, nested within the BCSN.** Abbreviations: BCSN, Bowel Cancer Screening in Norway; CRN, Cancer Registry of Norway; FIT, fecal immunochemical test; FU, follow-up; NorPD, Norwegian Prescription Database.

**Figure 2. Simplified version of the data generation process in CRCbiome.** The figure is created based on free images from Servier Medical Art (Creative Commons Attribution Liscence, creativecommons.org/liscences/by/3.0/) and Stockio (https://www.stockio.com/).

It is made available under a CC-BY-NC 4.0 International license .

## **Additional files**

Additional file 1: Supplementary tables (Additional file 1)

Additional\_file-1.docx

Contains two supplementary tables.

Additional file 2: Supplemetary figures (Additional file 2)

Additional\_file-2.docx

Contains a supplementary figure with figure title and legend.

Additional file 3: Ethical approval

Additional\_file-3.pdf

A translated version of the ethical approval for the CRCbiome study.

Additional file 4: Funding

Additional\_file-4A.pdf

Additional\_file-4B.pdf

Additional\_file-4C.pdf

The respective files contains documentation of funding (translated from Norwegian) from the Norwegian Cancer Society (4A-B) and the South Eastern Norway Regional Health Authority (4C). Documentation of funding from the Research Council of Norway can be submitted afterwords if required. The funding was provided to a large collabrotative project where the CRCbiome study only represented one part/work package.

Additional file 5: STROBE chechlist

Additional\_file-5.pdf

It is made available under a CC-BY-NC 4.0 International license .

Contains the STROBE checklist for observational studies.



